Graham Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.03M | Buy |
3,150
+1,240
| +65% | +$404K | 0.02% | 535 |
|
|
2025
Q1 | $516K | Sell |
1,910
-440
| -19% | -$119K | 0.01% | 764 |
|
|
2024
Q4 | $553K | Sell |
2,350
-1,260
| -35% | -$296K | 0.01% | 671 |
|
|
2024
Q3 | $993K | Buy |
3,610
+1,130
| +46% | +$311K | 0.02% | 437 |
|
|
2024
Q2 | $603K | Sell |
2,480
-5,783
| -70% | -$1.41M | 0.01% | 503 |
|
|
2024
Q1 | $1.23M | Buy |
+8,263
| New | +$1.23M | 0.02% | 341 |
|
|
2023
Q4 | – | Sell |
-1,427
| Closed | -$253K | – | 954 |
|
|
2023
Q3 | $253K | Sell |
1,427
-342
| -19% | -$60.6K | 0.01% | 763 |
|
|
2023
Q2 | $336K | Buy |
+1,769
| New | +$336K | 0.01% | 636 |
|
|
2022
Q4 | – | Sell |
-11,940
| Closed | -$2.39M | – | 1021 |
|
|
2022
Q3 | $2.39M | Sell |
11,940
-2,525
| -17% | -$505K | 0.09% | 166 |
|
|
2022
Q2 | $2.11M | Buy |
+14,465
| New | +$2.11M | 0.09% | 187 |
|